Date  |
|
| Feb 16, 2021 |
CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results |
| Jan 8, 2021 |
CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference |
| Jan 4, 2021 |
CEL-SCI Corporation Issues Letter to Shareholders |
| Dec 30, 2020 |
CEL-SCI Reports Fiscal 2020 Financial Results and Clinical & Corporate Developments |
| Dec 14, 2020 |
CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference |
| Dec 11, 2020 |
CEL-SCI Announces the Closing of Its $14.65 Million Bought Deal |
| Dec 8, 2020 |
CEL-SCI Announces Bought Deal Offering |
| Dec 7, 2020 |
CEL-SCI Announces Update on Phase 3 Cancer Trial Results |
| Dec 1, 2020 |
CEL-SCI’s LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies |
| Sep 18, 2020 |
CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis |